Dulaglutide, a GLP-1 receptor agonist, and Tirzepatide, a dual GIP/GLP-1 receptor agonist, are both primarily used in the management of Type 2 Diabetes and for weight loss. Our corpus indicates that GLP-1 receptor agonists generally offer cardiovascular protection and benefits beyond glucose control. Tirzepatide, in particular, has shown superior efficacy in glycemic control and weight reduction compared to dulaglutide, and evidence suggests it may also offer broader multi-organ protection, including cardiovascular and renal benefits. Both peptides contribute to the evolving understanding of incretin therapies in metabolic health.
| Dulaglutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 42 | 722 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | cohort · 1 rct · 15 review · 3 meta analysis · 6 other · 7 | n/a |
| Studies with explicit sample size | 6 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Dulaglutide and Tirzepatide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Dulaglutide COA records so far — not enough for a meaningful purity aggregate yet. Browse what we have →
We tested 7722 Tirzepatide batches across 1544 manufacturers, 99.69% avg purity.
No direct head-to-head trials in our corpus. Indirect comparison only. While both are incretin-based therapies, Tirzepatide's dual agonism of GIP and GLP-1 receptors appears to provide enhanced efficacy. Studies suggest Tirzepatide offers superior kidney protection compared to dulaglutide in patients with Type 2 Diabetes, significantly slowing eGFR decline. Furthermore, Tirzepatide has demonstrated noninferior cardiovascular safety when compared to dulaglutide, even while showing superior efficacy in glycemic control and weight reduction. The corpus also highlights Tirzepatide's potent efficacy in weight management, potentially positioning it as a first-line option where these are primary concerns, and suggests it may be a preferred choice for patients requiring optimal cardiovascular and renal protection. Dulaglutide, as a selective GLP-1 receptor agonist, is also recognized for its cardiovascular benefits, but Tirzepatide's dual mechanism appears to confer additional advantages in several key outcomes based on the studies indexed here.
Looking for vendor-level purity, endotoxin, and HPLC data on Dulaglutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.